These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 23290819)

  • 21. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.
    Gatzemeier U; von Pawel J; Gottfried M; ten Velde GP; Mattson K; de Marinis F; Harper P; Salvati F; Robinet G; Lucenti A; Bogaerts J; Gallant G
    J Clin Oncol; 2000 Oct; 18(19):3390-9. PubMed ID: 11013280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer.
    Kim DW; Kim SY; Kim HK; Kim SW; Shin SW; Kim JS; Park K; Lee MY; Heo DS
    Ann Oncol; 2007 Dec; 18(12):2009-14. PubMed ID: 17785767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer.
    Belani CP; Chakraborty BC; Modi RI; Khamar BM
    Ann Oncol; 2017 Feb; 28(2):298-304. PubMed ID: 27831503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Azithromycin enhances the favorable results of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Chu DJ; Yao DE; Zhuang YF; Hong Y; Zhu XC; Fang ZR; Yu J; Yu ZY
    Genet Mol Res; 2014 Apr; 13(2):2796-805. PubMed ID: 24782093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment Pokemon Level as a Predictor of Response to Cisplatin and Paclitaxel in Patients with Unresectable Non-Small Cell Lung Cancer.
    Zhang QL; Xing XZ; Li FY; Xing YJ; Li J
    Oncol Res Treat; 2015; 38(10):496-502. PubMed ID: 26451776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study.
    Tanioka M; Yamaguchi S; Shimada M; Nagao S; Takehara K; Nishimura M; Morita S; Negoro S; Fujiwara K; Kigawa J
    Med Oncol; 2017 Aug; 34(8):134. PubMed ID: 28681218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC).
    Pirker R; Krajnik G; Zöchbauer S; Malayeri R; Kneussl M; Huber H
    Ann Oncol; 1995 Oct; 6(8):833-5. PubMed ID: 8589023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A randomized trial of liposomal paclitaxel plus cisplatin as first-line therapy for advanced non-small cell lung cancer].
    Yang X; Zhang H; Nong J; Wang J; Li X; Zhang Q; Wang Q; Gao Y; Zhang S
    Zhongguo Fei Ai Za Zhi; 2012 Apr; 15(4):208-12. PubMed ID: 22510505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.
    Ranson M; Davidson N; Nicolson M; Falk S; Carmichael J; Lopez P; Anderson H; Gustafson N; Jeynes A; Gallant G; Washington T; Thatcher N
    J Natl Cancer Inst; 2000 Jul; 92(13):1074-80. PubMed ID: 10880550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer.
    Masuda N; Negoro S; Hausheer F; Nakagawa K; Matsui K; Kudoh S; Takeda K; Yamamoto N; Yoshimura N; Ohashi Y; Fukuoka M
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):533-42. PubMed ID: 20473611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients.
    Cheng YJ; Lee YC; Chiu WC; Tsai JW; Su YH; Hung AC; Chang PC; Huang CJ; Chai CY; Yuan SS
    Oncotarget; 2014 Nov; 5(22):11564-75. PubMed ID: 25344919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value: Changes in the Detection and Recognition Thresholds of Three Basic Tastes in Lung Cancer Patients Receiving Cisplatin and Paclitaxel and Its Association with Nutritional and Quality of Life Parameters.
    Turcott JG; Juárez-Hernández E; De la Torre-Vallejo M; Sánchez-Lara K; Luvian-Morales J; Arrieta O
    Nutr Cancer; 2016; 68(2):241-9. PubMed ID: 26943275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymeric micellar paclitaxel (Pm-Pac) prolonged overall survival for NSCLC patients without pleural metastasis.
    Lu J; Gu A; Wang W; Huang A; Han B; Zhong H
    Int J Pharm; 2022 Jul; 623():121961. PubMed ID: 35764263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931.
    Herndon JE; Fleishman S; Kosty MP; Green MR
    Control Clin Trials; 1997 Aug; 18(4):286-300. PubMed ID: 9257067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201.
    Ninomiya K; Hotta K; Hisamoto-Sato A; Ichihara E; Gotoda H; Morichika D; Tamura T; Kayatani H; Minami D; Kubo T; Tabata M; Tanimoto M; Kiura K
    Int J Clin Oncol; 2016 Feb; 21(1):81-7. PubMed ID: 26093520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of Clinical Efficacy of Nano-Albumin Paclitaxel Treatment for Advanced Cell Lung Cancer.
    Li X; Zhang Y; Zhi X; Li Y; Qian K
    J Nanosci Nanotechnol; 2020 Oct; 20(10):6019-6025. PubMed ID: 32384947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Seizure following chemotherapy (paclitaxel and cisplatin) in a patient of carcinoma cervix.
    Dana R; Spartacus RK; Mutha S; Bhat P
    Indian J Pharmacol; 2016; 48(6):736-738. PubMed ID: 28066118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the Efficacy and Safety of the Herbal Formula PM014 in a Cisplatin- and Paclitaxel-Treated Tumor-Bearing Mouse Model.
    Lee C; Jeong H; Lee KH; Park S; Gang MJ; Bae SK; Bae H
    Integr Cancer Ther; 2020; 19():1534735420924711. PubMed ID: 32590912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical insights into cisplatin-induced arrhythmia in a patient with locally advanced non-small cell lung cancer: a case report.
    Huang Y; Guo FZ; Dai S; Hu HY; Fu SY; Liu JW; Luo F
    Eur Rev Med Pharmacol Sci; 2022 Jan; 26(1):6-10. PubMed ID: 35049014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of docetaxel/cisplatin dosages of 75/60 and 60/60 mg/m(2) for the treatment of non-small cell lung cancer.
    Kim KS; Oh IJ; Ban HJ; Cho HJ; Kwon YS; Kim YI; Lim SC; Na KJ; Song SY; Choi S; Choi YD; Kim YC
    Exp Ther Med; 2012 Aug; 4(2):317-322. PubMed ID: 23139720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.